Trial
NCT05062577
A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
—
Condition
Opioid Use Disorder
Intervention
ASP8062
Why stopped
Due to corporate strategic considerations
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-06